Scandinavian ChemoTech: Comments on rights issue outcome - Redeye

Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue. In total, the offering was subscribed to 68.7%, and provides the company with cSEK9.8m in net proceeds. We make no changes to the valuation based on the announcement but argue that the outcome reduces the financing risk in the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/958169/scandinavian-chemotech-comments-on-rights-issue-outcome?utm_source=finwire&utm_medium=RSS